CARLSBAD, Calif.–Invitrogen Corporation (NASDAQ:IVGN), a leading provider of essential life sciences technologies for research, production and diagnostics, announced today it has entered into an exclusive agreement with Brendan Technologies (OTCBB:BDTE) to customize its StatLIA® assay analysis software to facilitate the analysis of protein samples. Financial terms of the agreement were not disclosed. Brendan’s StatLIA® software allows researchers to quantitate proteins with measurable accuracy and improve assay performance through automated quality control. StatLIA® also helps researchers troubleshoot sample preparation problems using advanced adaptive learning processes. This improves the drug/biomarker discovery, validation and development process with reduced timelines and costs. It will also allow researchers to make better informed judgments about the compatibility of separate data sets. The software will be designed to work with protein quantitation through mass spectrometry, which is an advanced scientific technique used to analyze compounds based on their molecular composition. For many researchers, it can be a tedious process, often requiring years of advanced study and training to perfect. “This software maximizes the value of our reagents through state-of-the-art computations and analysis of proteomics mass spectrometry,” said Kip Miller, Invitrogen’s Senior Vice President of BioDiscovery. “This is another example of how Invitrogen is dedicated to helping researchers access powerful, yet complex, technologies through simplifying specific application workflows, such as mass spectrometry. With the pending combination with Applied Biosystems, we will now have greater access to the mass spectrometry customers, allowing us to provide even more solutions addressing their needs.” “This agreement brings tremendous value to the life science customer by sourcing our software with Invitrogen’s superior technological capabilities,” said John Dunn, PhD, Chief Executive Officer of Brendan Technologies. “Our StatLIA software offers many innovative methodologies to combine advanced computational analysis with the automation, graphical tools, and data visualization needed for today’s life science laboratory. We are looking forward to working with this recognized leader in the global life sciences community.” About StatLIA® Software Brendan has been an innovative leader in the computation and analysis of immunoassays and bioassays, developing and perfecting several new methodologies and analytical processes. StatLIA® was developed by a team of biologists, statisticians and software engineers using the latest Microsoft development tools on a .NET platform. Brendan has begun placing a pre-release version its new StatLIA® Quantum software in several Big Pharma companies. StatLIA® Quantum offers a “quantum leap” advancement in software for the analysis and processing of immunoassay and bioassay testing technologies, which are critical to the drug development and drug release process. About Brendan Technologies, Inc. Brendan Technologies (OTCBB:BDTE), a developer and marketer of innovative analytical software, is actively providing software solutions to improve the accuracy, quality control, workflow, and regulatory compliance of immunoassay and bioassay testing in laboratories in the biopharmaceutical, clinical, research, veterinarian and agricultural industries. The Company’s customers, many of whom are Fortune 1000 organizations, represent some of the largest corporations in their respective fields. Brendan Technologies is continually redesigning and expanding its product lineup to better capitalize on the growing demand of its target markets for more advanced software. For more information, visit www.brendan.com. About Invitrogen Invitrogen Corporation (NASDAQ:IVGN) provides products and services that support academic and government research institutions and pharmaceutical and biotech companies worldwide in their efforts to improve the human condition. The company provides essential life science technologies for disease research, drug discovery, and commercial bioproduction. Invitrogen’s own research and development efforts are focused on breakthrough innovation in all major areas of biological discovery including functional genomics, proteomics, stem cells, cell therapy and cell biology — placing Invitrogen’s products in nearly every major laboratory in the world. Founded in 1987, Invitrogen is headquartered in Carlsbad, California, and conducts business in more than 70 countries around the world. The company employs approximately 4,700 scientists and other professionals and had revenues of approximately $1.3 billion in 2007. For more information, visit www.invitrogen.com. Safe Harbor Statement Certain statements contained in this press release are considered “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, and it is Invitrogen’s intent that such statements be protected by the safe harbor created thereby. Forward-looking statements include, but are not limited to; 1) StatLIA® will allow researchers to make better informed judgments about the compatibility of separate data sets; 2) the software will be designed to work with protein quantitation through mass spectrometry; 3) with the pending combination with Applied Biosystems, Invitrogen will have greater access to the mass spectrometry customers, and provide more solutions addressing their needs. Such forward-looking statements are subject to a number of risks, uncertainties and other factors that could cause actual results to differ materially from future results expressed or implied by such forward-looking statements. Potential risks and uncertainties include, but are not limited to, the risks: a) Brendan’s StatLIA® software may or may not allow researchers to improve accuracy or assay performance, troubleshoot sample preparation problems, improve the drug/biomarker discovery, validation and development process, or reduce timelines and costs; b) the agreement may or may not bring value to the life science customer; as well as other risks and uncertainties detailed from time to time in Invitrogen’s Securities and Exchange Commission filings.